Methods. Patients ≥18 years who received C/T for ≥48 hours while hospitalized in 9 acute care centers in Houston, TX from January 2016 through September 2018 were included. Demographic, microbiologic, treatment and clinical outcome data were retrospectively collected by chart review. In patients who received multiple inpatient courses of C/T, only the first course with C/T was assessed.

Results. 210 patients met inclusion criteria: 58% were non-white, 35% were female and 13% were immunocompromised. Median age was 61 years (IQR, 48 to 69). Median Charlson comorbidity index was 5 (IQR, 2 to 6). At the onset of the index episode, a significant proportion of patients required intensive care unit admission (44%), mechanical ventilation (37%) and pressor support (22%). Respiratory sources were the most common (50%) followed by urine (15%). Positive cultures were documented in 93% of the cases and PA was found in 86%. Majority (95%) of PA which were MDR. C/T use was guided by susceptibility testing of the index isolate in ca. 52%. In 5.7% of cases, C/T was used to escalate therapy without any documented C/T-susceptible organism. Half (51%) of the cohort received initial dosing appropriate for renal function while 36% receiving a lower than recommended dose. Clinical success (i.e., recovery from infection-related signs and symptoms) occured in 77%. The in-hospital mortality rate in our cohort was 15% with 26 of 31 deaths deemed infection-related.

Conclusion. We report a large multicenter observational cohort that received C/T. A 77% clinical success with the use of C/T was documented. These data support the use of C/T in critically ill patients infected with MDR PA.

Disclosures. William R. Miller, MD, Entasis Therapeutics (Scientific Research Study Investigator)Merck (Grant/Research Support)Shionogi (Advisor or Review Panel member) Laura A. Puzniak, PhD, Merck (Employee) Cesar A. Arias, MD, MSc, PhD, FIDSA, Entasis Therapeutics (Scientific Research Study Investigator)MeMed (Scientific Research Study Investigator)Merck (Grant/Research Support)

1609. Epidemiology and Susceptibility to Imipenem/Relebactam of Gram-Negative Pathogens from Patients with Lower Respiratory Tract Infections – SMART United States 2017-2018

Sibylle Lob, PhD[1]; Meredith Hackel, MPH[1]; Katherine Young, MS[2]; Mary Motyl, PhD[3]; Daniel F. Sahm, PhD[1]; [1]IHMA, Inc., Schaumburg, IL; [2]Merck & Co, Inc, Kenilworth, NJ; [3]Merck & Co., Inc., Kenilworth, NJ

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. Relebactam (REL) inhibits class A and C β-lactamases and was approved in the US combined with imipenem (IMI) and cilastatin for complicated urinary tract and intraabdominal infections. Using isolates collected as part of the global SMART surveillance program in the US, we evaluated the activity of IMI/REL against gram-negative pathogens (GNP) from patients with lower respiratory tract infections (LRTI), including a comparison of isolates from ICU and non-ICU wards.

Methods. In 2017-2018, 27 US hospitals each collected up to 100 consecutive aerobic or facultative GNP from LRTI patients per year. MICs were determined using CLSI broth microdilution and breakpoints.

Results. Among 3878 GNP isolates from LRTI, the most common species collected were *P. aeruginosa* (*Psa*, 33.3%), *K. pneumoniae* (10.9%), *E. coli* (10.4%), and *S. marcescens* (6.9%). Susceptibility of GNP is shown in the table.

IMI/REL inhibited 93% of *Psa* and Enterobacterales, which included 174 isolates of *Morganellaceae* that are not expected to be susceptible to IMI or IMI/REL. *S. marcescens* also showed low susceptibility to IMI, with improved but still reduced activity upon addition of REL. IMI/REL inhibited 83% of all GNP combined, 7-18 percentage points higher than the comparator β-lactams. Of the tested comparators, only amikacin exceeded the activity of IMI/REL.

Only *Psa* showed substantial differences in susceptibility between isolates from ICU (n=486) and non-ICU wards (n=611), with 63.4% and 70.2%, respectively, susceptible to IMI, 71.6/78.7% to cefepime, and 64.2/73.3% to piperacillin/tazobactam (P/T). Susceptibility to IMI/REL was high in both settings (91.4/93.6%). Among Enterobacterales, susceptibility was generally similar in ICU and non-ICU wards (IMI/REL, 92.5% in both settings; IMI, 86.3 and 87.1%, respectively; cefepime, 89.9/89.0%; P/T, 88.7/87.4%).

Table

	% Susceptible[a]							
Species (n)	IMI/REL	IMI	FEP	CAZ	ATM	P/T	CIP	AMK
All Enterobacterales (2036)	92.7	87.0	89.1	83.0	83.4	87.9	76.4	99.2
K. pneumoniae (422)	99.5	95.7	83.4	80.8	82.5	86.3	79.2	99.3
E. coli (404)	100	99.5	81.9	81.7	80.7	90.8	56.2	98.8
S. marcescens (269)	84.4	69.5	94.8	92.9	91.1	94.8	71.8	98.9
Psa (1292)	92.9	67.0	75.2	75.2	62.4	68.7	67.6	96.6
Enterobacterales + *Psa* (3328)	92.8	79.3	83.7	80.0	75.2	80.4	72.9	98.2
All GNP[b] (3878)	83.3	73.2	75.3	76.1	64.8	73.2	66.7	89.1

*Results for colistin are not shown because Enterobacterales and *Psa* are no longer considered susceptible to colistin per CLSI 2020 guidelines, as clinical and PK/PD data demonstrated limited clinical efficacy.
[a]Calculated using breakpoints appropriate for each species and assuming 0% susceptible for species with no breakpoints for any given drug.
IMI, imipenem; REL, relebactam; FEP, cefepime; CAZ, ceftazidime; ATM, aztreonam; P/T, piperacillin/tazobactam; CIP, ciprofloxacin; AMK, amikacin; *Psa, P. aeruginosa*; GNP, gram-negative pathogens

Conclusion. Although resistance rates have frequently been reported to be higher in ICU than non-ICU wards, this pattern was seen in the current study only among *Psa* isolates. IMI/REL showed activity >90% against both Enterobacterales and *Psa* from both ward types. These *in vitro* data suggest that IMI/REL could provide an important treatment option for patients with LRTI in the US, including those in ICUs.

Disclosures. Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Katherine Young, MS, Merck & Co., Inc. (Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) Mary Motyl, PhD, Merck & Co, Inc (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)

1610. Epidemiology and Treatment Heterogeneity in *Acinetobacter baumanii* Infections

Aisling Caffrey, PhD[1]; Haley J. Appaneal, PharmD[2]; Vrishali Lopes, MS[3]; Kerry LaPlante, PharmD[1]; [1]Rhode Island Infectious Diseases Research Program, Providence, RI; [2]1. Providence Veterans Affairs Medical Center, Providence, RI, United States 2. College of Pharmacy, University of Rhode Island, Kingston, RI, United States 3. School of Public Health, Brown University, Providence, RI, United States, Providence, Rhode Island; [3]PVAMC, Providence, RI

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. *Acinetobacter baumannii* is known as a highly resistant organism causing serious infections in intensive care populations. However, the epidemiology of infections caused by *Acinetobacter baumannii* and approaches to treatment are not well described in a national healthcare system.

Methods. Our retrospective cohort study included patients with positive *Acinetobacter baumannii* cultures collected from any source during hospitalizations at Veterans Affairs (VA) medical centers nationally from January 2010 to April 2019. We evaluated patient characteristics and utilized exposure mapping to identify treatment patterns, including treatment heterogeneity. Heterogeneity was defined as patterns of antibiotic treatment (drug and duration) not shared by any other patient.

Results. Our study included 7,551 admissions with positive *Acinetobacter baumannii* cultures. The mean age was 66.7 years (±12.1) and 97.4% were male. Most patients were admitted from other healthcare facilities (59.2%) and 20.8% were in intensive care during the admission. Most patients had their culture collected on the day after admission and the median time to culture completion was 4 days (interquartile range 3-5). *Acinetobacter baumannii* cultures were most commonly obtained from urine (33.6%), followed by skin and soft tissue (25.3%), lung (21.8%), blood (9.2%), and bone/joint (5.0%). The median length of hospital stay was 11 days, with inpatient mortality and 30-day mortality rates of 11.6% and 12.5%, respectively.

Treatment heterogeneity was high, with 88.5% of admissions having different antibiotic treatment patterns (drug and duration), with a median time to first change of 1 day and median of 3 changes. Only 2% of the admissions were treated with polymyxins and 3.0% with colistin. Carbapenems were used in 18.9% of the admissions and extended-spectrum cephalosporins in 31.7% of the admissions.

Conclusion. In VA hospitals, *Acinetobacter baumannii* infections are observed in both critical and non-critical patient populations, mostly among patients with healthcare exposures. *Acinetobacter baumannii* infections were found to have various sources of infection, mostly from urine and skin and soft tissue, and approaches to treatment were highly varied.

Disclosures. **Aisling Caffrey, PhD**, **Merck** (Research Grant or Support)**Pfizer** (Research Grant or Support)**Shionogi** (Research Grant or Support) **Haley J. Appaneal, PharmD**, **Shionogi, Inc.** (Research Grant or Support) **Kerry LaPlante, PharmD**, **Merck** (Advisor or Review Panel member, Research Grant or Support)**Ocean Spray Cranberries, Inc.** (Research Grant or Support)**Pfizer Pharmaceuticals** (Research Grant or Support)**Shionogi, Inc.** (Research Grant or Support)

1611. Evaluating Clinical Outcomes and Efficacy of Daptomycin in Combination with a Beta-Lactam for the Treatment of Vancomycin-Resistant *Enterococcus* (VRE) Bacteremia

Nerea Irusta, PharmD[1]; Ana Vega, PharmD[2]; Yoichiro Natori, MD, MPH[3]; Lilian M. Abbo, MD, FIDSA[4]; Lilian M. Abbo, MD, FIDSA[4]; Kailynn DeRonde, PharmD, BCIDP[2]; [1]Jackson Health System, Tampa, Florida; [2]Jackson Memorial Hospital, Miami, Florida; [3]Jackson Memorial Hospital/Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL; [4]University of Miami Miller School of Medicine & Jackson Health System, Miami, Florida

Session: P-71. Treatment of Antimicrobial Resistant Infections

Background. In-vitro studies have shown synergistic bactericidal activity with daptomycin (DAP) plus β-lactam antimicrobials against vancomycin resistant enterococci (VRE). There is a paucity of data regarding clinical outcomes with this combination in VRE bloodstream infections (BSI). The purpose of this study was to assess the efficacy of DAP plus a β-lactam with in-vitro activity vs. other therapies for treatment of VRE BSI.

Methods. IRB-approved, single-center, retrospective study of patients with VRE BSI from 01/2018-09/2019. Patients were excluded if < 18 years old, pregnant, or incarcerated. The primary outcome was time-to-microbiological clearance. Secondary outcomes included infection-related mortality, 30-day all-cause mortality, and incidence of recurrent BSI within 30 days of index culture. Targeted DAP doses were ≥ 8mg/kg and based on MIC. Factors associated with significance for outcomes, via univariate analysis, were evaluated with multivariable logistic regression (MLR), removed in a backward-step approach.

Results. A total of 85 patients were included, 23 of which received DAP plus a β-lactam. The comparator arm included linezolid or DAP monotherapy. Patients with combination therapy had significantly higher Charlson Comorbidity Index (CCI) (p=0.013) and numerically higher Pitt Bacteremia scores (PBS) (p=0.087) (Table 1). There was no difference seen in the primary outcome (Table 2). Secondary outcomes are provided in Table 2. The presence of polymicrobial infection and higher PBS were significantly associated with infection-related mortality (p=0.008 and p=0.005, respectively) by MLR. A Mann Whitney U test indicated that presence of infection-related